Sebastian Gensior

LinkedIn profiles boasting titles like ex-McKinsey, ex-Bain, ex-Novartis, or ex-Roche. It’s as if these professionals are collecting exes, not in their personal lives (well, hopefully), but in their résumés, brandishing them like badges of honor.

In European boardrooms, where modesty often masquerades as pragmatism, it is rare for a leader to sound the alarm with the urgency of Mario Draghi. His latest report on the EU pharmaceutical sector paints a stark picture: Europe, once a stalwart in global healthcare, is limping behind its competitors. Without

The Problem with Probability of Success (POS) in Biotech and Pharma Probability of Success (POS) is a widely used metric in biotech and pharma, offering a single probability that a drug candidate will successfully navigate the entire development process, from discovery through preclinical and clinical trials to regulatory approval and

Few metrics in modern oncology trials command the prominence of progression-free survival (PFS). As a measure of time until disease progression or death, PFS is beloved by clinical researchers for its speed and by companies for its clarity in demonstrating efficacy. For regulators, it is a convenient proxy, standing

Brussels has a new plan. The Competitiveness Compass, the European Commission’s latest attempt to reinvigorate the EU economy, comes with a familiar diagnosis: Europe has world-class talent but lacks the capital to scale its own innovations. The remedy? A bold—if somewhat overdue—proposal to mobilize pension funds

For decades, licensing deals have been the biotech-pharma relationship’s bread and butter—a veritable match made in heaven, or at least in a Bunsen burner-lit lab. The formula seems simple: a scrappy biotech develops a potential game-changing therapy, then hands it off to Big Pharma, who

Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5 billion budget for research and innovation from 2021 to 2027, have kept the pipettes full and the lab coats spotless. National initiatives in Germany and France add to the

Have you noticed something peculiar creeping into the corporate world? A proliferation of titles that sound less like professional roles and more like something you might overhear at the gym or a tactical training facility. This linguistic drift—from "teams" to "squads" and from "leaders&

Ah, the serial founder. That darling of venture capital, the endlessly inventive entrepreneur who builds company after company, racking up exits like trophies on a mantelpiece. Their LinkedIn profiles read like a highlight reel of bold visions, impressive exits, and the occasional stealth startup that never quite gets explained. But

The Weighted Average Cost of Capital (WACC) is a foundational metric in corporate finance, designed to evaluate the opportunity cost of capital and guide investment decisions. However, in the context of biotech and pharma—industries dominated by high uncertainty, skewed outcomes, and extreme risks—WACC becomes problematic. Its reliance on